News Focus
News Focus
icon url

DewDiligence

11/02/22 4:38 PM

#244399 RE: dewophile #244395

ENTA is a great fit for GSK.

Many investors mistakenly think ENTA would be worth more to ABBV than to other suitors because of the Mavyret royalty stream, but such thinking is mathematically unsound (#msg-159261015).